United Therapeutics (UTHR) Cash from Investing Activities (2009 - 2026)

United Therapeutics has reported Cash from Investing Activities for 18 years, with the latest figure at $743.7 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 551.55% year-over-year to $743.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $357.1 million (up 173.96% YoY) and the FY2025 annual result came in at -$551.3 million, down 232.14% from the prior year.
• Cash from Investing Activities advanced to $743.7 million in Q1 2026 per UTHR's latest filing, from -$227.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $743.7 million in Q1 2026 and troughed at -$359.2 million in Q1 2022.
• A 5-year average of -$54.2 million and a median of -$164.7 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities sank 5601.59% in 2022, then soared 551.55% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$189.3 million in 2022, then jumped by 122.24% to $42.1 million in 2023, then sank by 392.64% to -$123.2 million in 2024, then tumbled by 84.74% to -$227.6 million in 2025, then surged by 426.76% to $743.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $743.7 million, -$227.6 million, and $140.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.